Stay updated with breaking news from Clinical Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a...
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead c
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...
15.02.2024 - First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 ...
Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough...